Navigation Links
Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
Date:3/24/2009

or pixantrone and gain approval in 2009, the potential failure of pixantrone to prove safe and effective for treatment of non-Hodgkin's lymphoma, our ability to identify and negotiate product partnerships, our ability to raise additional capital to fund our continued operations, determinations by regulatory, patent and administrative governmental authorities including but not limited to decisions regarding the review and approval of applications submitted to the FDA or the EMEA, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:
    Cell Therapeutics, Inc.
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    Lindsey Jesch
    T : 206.272.4347
    F : 206.272.4434
    E: media@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:
    Cell Therapeutics, Inc.
    Ed Bell
    T: 206.272.4345
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Tuesday, March 24, 2009
2. Oxygen Biotherapeutics, Inc. Expands Board of Directors
3. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
4. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
5. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
6. Cell Therapeutics, Inc. (CTI) BIO CEO Presentation to be Webcast
7. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
8. Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference
9. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
11. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... State University have developed a technique for controlling the ... voltages, opening the door to a new generation of ... hinges on the fact that the oxide "skin" of ... acts as a surfactant, lowering the surface tension ... researchers used a liquid metal alloy of gallium and ...
(Date:9/15/2014)... Calif. , Sept. 15, 2014 ... new viral transport solution for safe ambient temperature ... to molecular testing. Importantly, the infectivity of agents in ... while maintaining the integrity of the viral nucleic ... of the recent Ebola epidemic in ...
(Date:9/15/2014)... 2014 Die zweite jährliche International ... bis 18. Oktober stattfinden. Die IPAW ist eine ... (PPTA) und ihrer Mitgliedsunternehmen und ... Bewusstsein für die Gewinnung von Quellplasma zu steigern ... und Verbessern von Leben zu würdigen , ...
(Date:9/14/2014)... September 15, 2014 UMBC’s Biotechnology ... on Tuesday, October 21, 2014, from 12:00 to 1:00 ... the program’s innovative curriculum and practice-oriented instruction, designed for ... degree can help advance their career in the biotechnology ... online . , About UMBC’s Biotechnology Graduate Programs, ...
Breaking Biology Technology:Researchers control surface tension to manipulate liquid metals 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 2International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 3UMBC Biotechnology Graduate Programs’ Virtual Info Session, October 21, 2014 2
... , , , ... ) announced that it will be hosting a conference call to discuss today,s ... begin at 8:30 a.m. Eastern Time (ET)/5:30 a.m. Pacific Time (PT). , ... accessed through a link that is posted on the home page of Nektar,s ...
... ... firms have to follow a rigorous documentation process to comply with a ... corporate agreements these firms are faced with the daunting task of sharing ... affordable unlimited use facility to share thousands of confidential documents securely and ...
... question, researchers with the U.S. Department of Energy,s ... that the selective placement of strain can alter ... correlated electron materials. This unique class of materials ... display properties such as colossal magnetoresistance and high-temperature ...
Cached Biology Technology:Nektar Therapeutics to Host Conference Call to Discuss Today's Announcement of a New Partnership for NKTR-118 and NKTR-119 2Life Science Firms are Turning to Firmex to do Deals Online 2Life Science Firms are Turning to Firmex to do Deals Online 3Strain on nanocrystals could yield colossal results 2Strain on nanocrystals could yield colossal results 3
(Date:9/15/2014)... gut microbes influence processes from digestion to disease resistance. ... biodiverse terrestrial ecosystems on the planet, more is known ... tropics. Smithsonian scientists and colleagues working on Panama,s Barro ... single tree were home to more than 400 different ... species contained more than 7,000 different kinds. , Bacteria ...
(Date:9/15/2014)... a morphine regimen can result in better pain control ... the dosage of the opioid needed to be effective, ... University. , The result could bring significant relief to ... felt in the arms and legs and associated with ... need for better treatments for neuropathic pain," said Fletcher ...
(Date:9/15/2014)... print issue of the journal Science comes ... Mexico, Montana and even the Netherlands, thanks to the ... the norm in these connected times. Yes, the research ... innovations in biology, medicine, biotechnology and agriculture. It could ... with that one, that one knew another one, and ...
Breaking Biology News(10 mins):Smithsonian scientists discover tropical tree microbiome in Panama 2IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2Collaboration drives achievement in protein structure research 2
... early bird rates for the premier bone meeting in 2012. ... 21-24, 2012 will be held in in the magnificent city ... register by December 9, 2011 at http://www.iof-ecceo12.org ... key thought leaders... Plenary lectures:, The conundrum ...
... now possible to use dental X-rays to predict who is ... at the Sahlgrenska Academy reported in the journal Nature ... the University of Gothenburg,s Sahlgrenska Academy and Region Vstra Gtaland ... in the lower jaw is linked to a greater chance ...
... and more solar modules are appearing on rooftops, and ... into the grid. Multi-junction solar cells are particularly efficient ... to 43 percent - twice the level of conventional ... consist of several semi-conductor layers that combine to transform ...
Cached Biology News:Register now for the European Congress on Osteoporosis & Osteoarthritis in Bordeaux 2Dental X-rays can predict fractures 2Fraunhofer researchers receive the Franco-German Business Award 2011 2
... Dinitro-5,5'-dithiodibenzoic acid , DTNB , Ellman's reagent ... , *CAS-No.: 69-78-3 *Storage: ... with a reactive grouping not present in the ... reagent which will react directly with the product ...
Borrelia Burgdorfen (IgG) -Ab EIA Sample Size: 100 l...
... RNase Inhibitor (patent pending) is a protein ... binds and inhibits the most common and ... 1 and T1. SUPERaseIn can be used ... be problematic. It is ideal for in ...
... Recombinant Ribonuclease Inhibitor is a ... ribonucleases such as RNase A. ... Recombinant Ribonuclease Inhibitor is an ... weight ~52 kDa. RNaseOUT inhibits ...
Biology Products: